Evidence map›Paper›PMID 41509400›Full record

ArticlebioRxiv : the preprint server for biology2026

Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer.

Atsushi Ito, Sung Wook Kang, Hee-Jin Jang, Ji Seon Shim, Claire Lee, Priyanka Ranchod, Gena Lee, Sonali Mitra, Jiyeon Jeon, Ayu H Syarif and 12 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Atsushi ItoSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.
Sung Wook KangSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.
Hee-Jin JangSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.
Ji Seon ShimSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.
Claire LeeSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.
Priyanka RanchodSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.
Gena LeeSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.
Sonali MitraSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.
Jiyeon JeonSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.
Ayu H SyarifDivision of Pulmonary Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
Yun ZhangDivision of Pulmonary Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
Jinyoung ByunInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, 77030.
Younghun HanInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, 77030.
Joshua MaloDepartment of Pulmonary and Critical Care Medicine, University of Arizona, Tucson, AZ 85721.
Meera PatelDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030.
R Taylor RipleyDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030.
Shawn S GrothDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030.
Farrah KheradmandDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030.
Bryan M BurtDivision of Thoracic Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 99095.
Francesca PolverinoDivision of Pulmonary Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
Christopher I AmosInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, 77030.
Hyun-Sung LeeSystems Onco-Immunology Laboratory, David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030.ORCID 0000-0001-8259-046X

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
B cell-adaptive Immune Profile in Emphysema-predominant COPDR01HL149744 · NHLBI · UNIVERSITY OF ARIZONA · PI POLVERINO, FRANCESCA · 2020 to 2024
$3.4M
Proteomic determinants of response to checkpoint blockade in malignant pleuralmesotheliomaR37CA248478 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Bryan Michael Burt · 2021 to 2026
$2.9M
Protective effects of metformin against cigarette smoke-induced lung pathologies via regulation of fatty acids metabolismR01HL171622 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI Francesca Polverino · 2024 to 2026
$2.2M
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPYR21AI159379 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI LEE, HYUN-SUNG, REDONDO, MARIA JOSE · 2023 to 2024
$440k
Heterogeneous Genetic Architecture in Lung Cancer RiskR03CA277197 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BYUN, JINYOUNG · 2024 to 2025
$156k
NCI NIH HHS P30 CA125123NCI NIH HHS R03 CA277197NCI NIH HHS R37 CA248478NHLBI NIH HHS R01 HL149744NHLBI NIH HHS R01 HL171622NIAID NIH HHS R21 AI159379
6 · The paper itself

Abstract

Objective: Neoadjuvant chemoimmunotherapy has improved outcomes in resectable non-small cell lung cancer (NSCLC), yet its real-world implementation is often challenged by surgical delays, immune-mediated fibrosis, and postoperative complications. Smokers with NSCLC, despite a high risk for surgical morbidity, show enhanced responses to neoadjuvant chemoimmunotherapy. This study aimed to identify smoking-associated immune cell determinants that could guide treatment strategies. Methods: Single-cell RNA sequencing (scRNAseq) was performed on 61 lung tissues from non-smokers and smokers to identify smoking-related immune compositions. The scRNAseq data from 19 invasive lung adenocarcinomas were used to validate their presence in the tumor-immune microenvironment. Bulk RNA sequencing data from 102 resected NSCLC and 24 NSCLC patients treated with neoadjuvant chemoimmunotherapy followed by surgery were used for Results: Among 135 lung cellular phenotypes, two natural killer (NK) cell subsets were strongly associated with smoking and chronic obstructive pulmonary disease (COPD) severity. "Stress-responsive" NK (NK Conclusions: Intratumoral NK cell phenotyping may aid in therapeutic stratification in patients with NSCLC. NK

Indexed as

cellular biomarkerchronic obstructive pulmonary diseasenatural killer cellneoadjuvant chemoimmunotherapynon-small cell lung cancerpredictive markerprognostic markersingle-cell RNA sequencingsmoking

Identifiers

PMID41509400
PMCPMC12776338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.